Fmr LLC Raises Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

FMR LLC lifted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 0.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,314,014 shares of the company's stock after acquiring an additional 21,133 shares during the quarter. FMR LLC owned 15.00% of Krystal Biotech worth $675,833,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in KRYS. Entropy Technologies LP bought a new stake in shares of Krystal Biotech in the fourth quarter valued at $548,000. Janney Montgomery Scott LLC boosted its position in shares of Krystal Biotech by 42.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock valued at $8,239,000 after acquiring an additional 15,545 shares during the last quarter. Principal Financial Group Inc. lifted its position in Krystal Biotech by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 123,453 shares of the company's stock valued at $19,340,000 after purchasing an additional 3,727 shares during the last quarter. abrdn plc raised its position in shares of Krystal Biotech by 32.5% during the 4th quarter. abrdn plc now owns 57,033 shares of the company's stock valued at $8,935,000 after buying an additional 13,979 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after acquiring an additional 433 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Up 1.3 %

Krystal Biotech stock traded up $2.09 during trading hours on Monday, hitting $167.09. The stock had a trading volume of 31,245 shares, compared to its average volume of 294,799. The stock's 50-day moving average price is $173.96 and its 200-day moving average price is $172.21. The stock has a market capitalization of $4.83 billion, a P/E ratio of 55.88 and a beta of 0.75. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34.

Remove Ads

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period last year, the business posted $0.30 EPS. The company's revenue was up 116.4% compared to the same quarter last year. On average, research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 14.10% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital lifted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. HC Wainwright restated a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Friday, February 28th. Citigroup increased their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Finally, Jefferies Financial Group started coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).